• LY2603618: Chk1 Inhibitor Research Guide

  2026-08-18

  LY2603618 is a selective Chk1 inhibitor that disrupts checkpoint control, DNA damage signaling, and mitotic progression in cancer research models. Product information supports its use in non-small cell lung cancer and colon cancer studies, including gemcitabine-combination experiments, while emphasizing research-use-only boundaries.

• Nonselective β-Blockers and HCT Engraftment

  2026-08-18

  This study shows that carvedilol, a nonselective β-adrenergic receptor antagonist, can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation (HCT), whereas β1-selective metoprolol does not produce the same pattern. Mouse experiments and human transplant cohorts connect broad β-adrenergic blockade with delayed platelet engraftment and lower survival, particularly when posttransplant chemotherapy is used for graft-versus-host disease prophylaxis.

• WRN–MMR Synthetic Lethality in MSI Colorectal Cancer

  2026-08-17

  The reference study identifies a causal p53/PUMA apoptotic mechanism behind the selective dependence of mismatch repair-deficient, microsatellite-unstable colorectal cancer cells on WRN helicase. Its genetic, isogenic, pharmacologic, and xenograft experiments support p53 status as a practical determinant of response to WRN-directed strategies, while also highlighting the need to distinguish WRN biology from broader RecQ-helicase inhibition.

• STNvac Builds TLS Immunity in Liver Cancer

  2026-08-17

  Lin et al. developed a spleen-targeted neoantigen mRNA vaccine, STNvac, that produced strong antitumor activity in orthotopic hepatocellular carcinoma models. The study links efficacy to ISG15-positive CD8-positive T cells, GZMA-F2R-mediated interactions with antigen-presenting cells, and tertiary lymphoid structure formation, providing a mechanistic framework for organ-targeted cancer vaccination.

• miR-24-3p/Sp1/PI3K Axis in Doxorubicin Heart Failure

  2026-08-16

  The reference study identifies miR-24-3p as a pathogenic regulator of doxorubicin-induced heart failure, acting through suppression of the Sp1/PI3K signaling axis. By combining rat and H9c2 cardiomyocyte models with genetic manipulation, pathway inhibitors, and dual-luciferase validation, the work provides a mechanistic framework for studying apoptosis and oxidative stress in myocardial injury.

• FAST Nutraceutical Nanoparticles: Study Analysis

  2026-08-15

  The reference study presents Facilitated Self-Assembling Technology (FAST) as a food-grade, surfactant-free route for producing stable nanoparticles from poorly soluble nutraceuticals. Its findings indicate that hybrid formulations can improve colloidal behavior and simulated gastric stability while retaining cellular compatibility, although further quantitative bioavailability and scale-up studies are needed.

• Sodium Ascorbate in Cancer Research Workflows

  2026-08-14

  Sodium Ascorbate gives oncology laboratories a practical way to probe ROS-linked cancer cell injury in glioblastoma and prostate models. This guide connects stock preparation, time-resolved assays, and troubleshooting with a separate biomarker framework for interpreting tumor–immune interactions in ESCC research.

• 131I-MIBG + PARP Inhibition in PPGL Models

  2026-08-14

  This study tests a synthetic-lethality strategy for norepinephrine transporter-overexpressing pheochromocytoma and paraganglioma models by combining 131I-MIBG with the PARP inhibitor fluzoparib. The combination produced stronger cell-cycle arrest and apoptosis than either treatment alone, while SDHB suppression preferentially increased sensitivity to fluzoparib rather than to 131I-MIBG.

• CCCP: Mitochondrial Proton Gradient Disruption

  2026-08-13

  CCCP, or carbonyl cyanide m-chlorophenyl hydrazine, is a research uncoupler that dissipates the mitochondrial proton motive force and suppresses gradient-dependent ATP synthesis. Its controlled use can separate mitochondrial bioenergetic effects from morphology changes in cellular and bacteriophage λ assays.

• TaqI Restriction Endonuclease Protocol Guide

  2026-08-13

  TaqI Restriction Endonuclease (SKU K3053) provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA when a 5′-TCGA-3′ site is present. It is suitable for research workflows requiring sticky ends and quick gel-based QC, but it should not be used for diagnostic, medical, or blunt-end applications.

• SGI-1027 Induces Apoptosis in Huh7 Cells

  2026-08-12

  The reference study shows that the non-nucleoside DNA methyltransferase inhibitor SGI-1027 reduces Huh7 hepatocellular carcinoma cell viability primarily through apoptosis rather than detectable cell-cycle redistribution. Its findings connect Bcl-2 suppression and Bax induction with a mitochondrial apoptotic phenotype, while also defining important limits for interpreting epigenetic mechanism and translational relevance.

• DRB in Cell-Fate Assay Design

  2026-08-12

  5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is more than a transcriptional elongation inhibitor: it can help separate RNA polymerase II-dependent effects from mRNA-translation mechanisms during stem-cell fate studies. This article presents an assay-centered framework grounded in YTHDF1 phase-separation research.

• Liposomal Chlorin e6 PDT Drives Pyroptosis

  2026-08-11

  The reference study shows that liposomal Chlorin e6-mediated photodynamic therapy can kill 4T1 breast cancer cells through mitochondrial oxidative damage, mitochondrial DNA release, and caspase-1-associated pyroptosis. In mouse models, this treatment also promoted immunogenic cell death and anti-tumor immunity, with stronger tumor control after combination with the immune checkpoint inhibitor BMS202.

• Calpeptin and the Translational Logic of Fibrosis

  2026-08-11

  Calpeptin offers translational researchers a mechanistic way to interrogate how calcium-dependent proteolysis intersects with fibroblast activation, inflammatory signaling, and tissue injury. This thought-leadership analysis connects cell-death biology with pulmonary fibrosis research while defining the controls, evidence standards, and strategic positioning needed to move from biochemical inhibition to credible disease insight.

• Mithramycin A Workflows for Gene Regulation

  2026-08-10

  Mithramycin A combines G-C-rich DNA binding with practical control of transcriptional programs, supporting c-myc studies, leukemia research, and differentiation assays. This workflow-focused guide also shows how to test its value as a mechanistic probe in doxorubicin-related cardiac models without overstating evidence.

11541 records 1/770 page Next 12345 下5页 Last page